The production of monoclonal antibodies to rubella haemagglutinin and their use in antibody-capture assays for rubella-specific IgM

Tedder, Richard S.; Yao, J. L.; Anderson, M. C.

doi:10.1017/s0022172400070182

Cited by 64 publications

(27 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of a monoclonal detector antibody should considerably increase these ratios as it has done for the rubella MACRIA (Tedder, Yao and Anderson, 1982). However, for the reasons stated above in relation to antigen purification, it may be that such an improvement in T/N ratios would not help to differentiate positive from negative sera.…”

Section: Discussionmentioning

confidence: 99%

Antibody capture radioimmunoassay (MACRIA) for coxsackievirus B4 and B5-specific IgM

Morgan‐Capner

McSorley

1983

J. Hyg.

View full text Add to dashboard Cite

SUMMARYAn antibody capture radioimmunoassay was established for the detection of coxsackievirus B4 and B5-specific IgM. A significant feature of the assay was the use of an unrefined coxsackievirus B (CBV) antigen. The antigen was prepared by freeze thawing, ultrasonication and low speed centrifugation of infected Vero cells with no purification or concentration of the antigen being performed. Results of sera tested were expressed as a serum ratio (SR) by comparison with a low positive control serum. To establish an SR indicating positivity in the assays, 100 antenatal sera collected in late February were tested. The mean SR was calculated and the mean plus three standard deviations was taken as the minimum SR indicating positivity. Although resulting in a relatively insensitive assay, such a value was required to exclude sera giving a low level of reactivity which may be due to residual enterovirus-specific IgM resulting from a remote infection.The homologous CBV-IgM assay was positive in four cases of CBV4 infection and six cases of CBV5 infection. For the CBV4 IgM assay, ten of 20 (50 %) sera from infections with CBV other than CBV4 were positive and nine of the 13 (69 %) sera from infections with echoviruses or coxsackieviruses A were positive. Five of 18 (27 %) sera with an elevated CBV neutralization titre were positive in the CBV4-IgM assay. For the CB5-IgM assay seven of 18 (39 %) sera from infections with CBV other than CBV5 were positive and nine of 13 (69 %) sera from infections with echoviruses or coxsackieviruses A were positive. The nine sera that were positive from this group in the CBV5-IgM assay were the same nine as were positive in the CBV4-IgM assay. Two of the 18 (11 %) sera with an elevated CBV neutralization titre were positive in the CBV5-IgM assay. These two sera were also positive in the CBV4-IgM assay and had an elevated monotypic CBV4 neutralization titre. None of the sera giving positive results gave significant reactivity when tested with control antigen. Twelve rheumatoid factor containing sera and 46 sera from other infections were negative in both assays. Of 24 sera from confirmed CBV infection, seven gave a positive monotypic CBV4 or 5-IgM response, ten were positive in both assays and seven were negative in both assays. Thus the CBV4 and 5-IgM assays developed appeared to be specific for an enterovirus infection but because of the cross-reactivity were not type-specific or group-specific.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibody capture radioimmunoassay (MACRIA) for coxsackievirus B4 and B5-specific IgM

Morgan‐Capner

McSorley

1983

J. Hyg.

View full text Add to dashboard Cite

show abstract

“…Female BALB/c mice were immunized separately with purified HBsAg from each carrier, in an equal volume of TiterMax (Sigma). After two boosts approximately 2 months apart and a final tail vein injection, the spleens from the mice were removed and fused with JKAg myeloma cells using 50 % polyethylene glycol, as described previously (Tedder et al, 1982).…”

Section: Methodsmentioning

confidence: 99%

“…The immunoglobulin fraction of ascites fluid was purified and labelled with 125 I (Amersham), as described previously (Tedder et al, 1982).…”

Section: Methodsmentioning

confidence: 99%

A ‘first loop’ linear epitope accessible on native hepatitis B surface antigen that persists in the face of ‘second loop’ immune escape

Ijaz

Ferns

Tedder

2003

Journal of General Virology

View full text Add to dashboard Cite

Murine monoclonal antibodies (mAbs) were raised following immunization with native mutant hepatitis B surface antigen (HBsAg) purified from human sera. A set of antibodies binding to a linear epitope carried between residues 121 and 129 of the s region was demonstrated. These antibodies were shown by cross-competition assays to bind to a single epitope whose antigenicity was influenced by the TTP motif lying between residues 125 and 127. This first loop epitope remained accessible on the surface of HBsAg in spite of major second loop mutations abrogating the normal a conformational epitopes. The mAb and its binding region in the first loop are important diagnostically and may represent an importance immunological target, one that is stable in the face of immunologically driven escape.

show abstract

“…per ml control used gave zone diameters ranging from 7'5 to 8-5 mm in the RH test and an HI titre of 20. Post-immunization specimens were tested for anti-rubella IgM using a modified MACRIA incorporating rubellaspecific monoclonal antibody (Tedder, Yao & Anderson, 1982). Specimens from the Almevax study were re-examined by the modified MACRIA in parallel with the specimens from the Cendevax study.…”

Section: Rubella Antibody Testsmentioning

confidence: 99%

The immunoglobulin M response to rubella vaccine in young adult women

Mortimer¹,

Edwards²,

Porter³

et al. 1984

J. Hyg.

Self Cite

View full text Add to dashboard Cite

SUMMARYRubella vaccination histories were taken from 333 young women working in the head office of a retail organization: 29 % said they had had vaccine and 47 % said they had not. The remainder did not know. Forty-six per cent of those < 25 years old (who should have been offered vaccine at school), and 6 % of those > 25 years old, said they had been vaccinated. When screened for immunity to rubella by radial haemolysis (RH) 3 % had a low level of antibody (< 15 i.u./ml) and 11 % had no antibody. After immunization with Cendevax the specific rubella IgM response was measured by an IgM antibody capture radioimmunassay (MACRIA). It was only detectable in the group without RH antibody, and was present in 26/31 of them. The IgM response to Cendevax was strongest in specimens taken 20-39 days after immunization, but in 10 out of 11 cases tested was still present at around 71 days. The specific IgM responses to Cendevax were very similar to those in women given Almevax in an earlier study, when measured in parallel tests.Taking both vaccines together, specific IgM was present in 35 out of 36 vaccinees without pre-existing antibody tested between 40 and 77 days post-immunization. Detection of specific IgM by MACRIA would therefore be an effective means of determining susceptibility retrospectively in rubella vaccinees found to be pregnant.

show abstract

The production of monoclonal antibodies to rubella haemagglutinin and their use in antibody-capture assays for rubella-specific IgM

Cited by 64 publications

References 11 publications

Antibody capture radioimmunoassay (MACRIA) for coxsackievirus B4 and B5-specific IgM

Antibody capture radioimmunoassay (MACRIA) for coxsackievirus B4 and B5-specific IgM

A ‘first loop’ linear epitope accessible on native hepatitis B surface antigen that persists in the face of ‘second loop’ immune escape

The immunoglobulin M response to rubella vaccine in young adult women

Contact Info

Product

Resources

About